China SXT Pharmaceuticals, Inc. (SXTC) Net income 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$6.2MFY2026 · since FY2017: $1.2M → -$6.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$6.2M | -87.8% |
| FY2025 | -$3.3M | -6.6% |
| FY2024 | -$3.1M | +47.8% |
| FY2023 | -$5.9M | -3.5% |
| FY2022 | -$5.7M | -108.7% |
| FY2021 | -$2.7M | +73.3% |
| FY2020 | -$10.3M | -768.4% |
| FY2019 | $1.5M | +29.6% |
| FY2018 | $1.2M | +0.2% |
| FY2017 | $1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net marginSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →